Supplementary Figures 1-5 and Supplementary Table 1 from Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 1. Outline of the open-label single arm two-stage phase II clinical trial evaluating single agent IPH2101 in patients with smoldering multiple myeloma; Supplementary Figure 2. Absolute NK-cell counts in peripheral blood following infusion of IPH2101 in patients with smoldering multiple myeloma; Supplementary Figure 3. IPH2101 does not affect the viability of KIR2D+ cells; Supplementary Figure 4. Loss of KIR2D molecules on the NK-cell surface following IPH2101-induced trogocytosis; Supplementary Figure 5. IL-2 activation of patient NK-cells ex vivo significantly increases baseline cytotoxic function; Supplementary Table 1. Patient and disease characteristics, response at end of trial and disease status at last evaluable follow-up point.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361921529